Asuragen QuantideX qPCR BCR-ABL IS Kit

Asuragen has launched its QuantideX qPCR BCR-ABL IS kit, the first FDA cleared molecular diagnostic test for monitoring BCR-ABL1 transcripts in myeloid leukemia. The kit uses armored DNA technology to create World Health Organization Primary standard-aligned RNA-based calibrators. The assay reports patient results directly on the International Scale in accordance with the European LeukemiaNET and the National Comprehensive Cancer Network, the company said.